» Articles » PMID: 14761195

Structural Basis for the Synthesis of Indirubins As Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-dependent Kinases

Abstract

Pharmacological inhibitors of glycogen synthase kinase-3 (GSK-3) and cyclin-dependent kinases have a promising potential for applications against several neurodegenerative diseases such as Alzheimer's disease. Indirubins, a family of bis-indoles isolated from various natural sources, are potent inhibitors of several kinases, including GSK-3. Using the cocrystal structures of various indirubins with GSK-3beta, CDK2 and CDK5/p25, we have modeled the binding of indirubins within the ATP-binding pocket of these kinases. This modeling approach provided some insight into the molecular basis of indirubins' action and selectivity and allowed us to forecast some improvements of this family of bis-indoles as kinase inhibitors. Predicted molecules, including 6-substituted and 5,6-disubstituted indirubins, were synthesized and evaluated as CDK and GSK-3 inhibitors. Control, kinase-inactive indirubins were obtained by introduction of a methyl substitution on N1.

Citing Articles

Isatin Bis-Imidathiazole Hybrids Identified as FtsZ Inhibitors with On-Target Activity Against .

Morigi R, Esposito D, Calvaresi M, Marforio T, Gentilomi G, Bonvicini F Antibiotics (Basel). 2024; 13(10).

PMID: 39452258 PMC: 11505029. DOI: 10.3390/antibiotics13100992.


Design, Synthesis, Biological Evaluation and Molecular Docking Studies of a New Series of Maleimide Derivatives.

Eyilcim O, Gunay F, Ng Y, Ulucan Acan O, Turgut Z, Tahir Gunkara O ChemistryOpen. 2024; 13(12):e202400058.

PMID: 39313991 PMC: 11625963. DOI: 10.1002/open.202400058.


Oxindole-benzothiazole hybrids as CDK2 inhibitors and anticancer agents: design, synthesis and biological evaluation.

Abdel-Mohsen H BMC Chem. 2024; 18(1):169.

PMID: 39272187 PMC: 11396129. DOI: 10.1186/s13065-024-01277-1.


Repurposing of CDK Inhibitors as Host Targeting Antivirals: A Mini- Review.

Liu M, Peng W, Ji X Mini Rev Med Chem. 2024; 25(3):178-189.

PMID: 39185650 DOI: 10.2174/0113895575311618240820103549.


Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment.

Ma C, Cui S, Xu R Curr Med Chem. 2024; 31(29):4657-4686.

PMID: 38204232 DOI: 10.2174/0109298673277543231205072556.